Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Müller RP, Kurtz J, Morgan DA, Dubois JB, Salamon E, Mirimanoff RO, Leer JW, Bolla M, Kuten A, Renaud A, Schulz U, Koper PC, Van den Weyngaert D, Storme GA, Calitchi GH, Budach W, Roth S, Poulsen M, Dominguez MA, Monpetit E, Kovner F, Biete Sola A, Calvo F, Vrieling C, Barillot I, Borger J.
Statistics Department, EORTC Headquarters, Brussels, Belgium. sandra.collette@eortc.be
The EORTC 22881-10882 trial in 5178 conservatively treated early breast cancer patients showed that a 16 Gy boost dose significantly improved local control, but increased the risk of breast fibrosis. To investigate predictors for the long-term risk of fibrosis, Cox regression models of the time to moderate or severe fibrosis were developed on a random set of 1797 patients with and 1827 patients without a boost, and validated in the remaining set. The median follow-up was 10.7 years. The risk of fibrosis significantly increased (P<0.01) with increasing maximum whole breast irradiation (WBI) dose and with concomitant chemotherapy, but was independent of age. In the boost arm, the risk further increased (P<0.01) if patients had post-operative breast oedema or haematoma, but it decreased (P<0.01) if WBI was given with >6 MV photons. The c-index was around 0.62. Nomograms with these factors are proposed to forecast the long-term risk of moderate or severe fibrosis.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on